Zimbabwe has turned down a substantial American healthcare agreement worth $367m (£272m) spanning five years due to the United States' demand for confidential data.
This move became public after a internal memorandum from December was disclosed, which showed Head of State Emmerson Mnangagwa felt the agreement was "lopsided".
A government spokesperson has since explained that the US was demanding access to genetic material for research and commercial gain but was unwilling to guarantee the benefits from any future treatments.
"We must now begin the difficult and regrettable process of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had provided more than $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for more talks to find a agreement agreeable to both sides so the nation's vital HIV programme can continue.
Broader Context
Zimbabwe's decision follows a comparable situation in Kenya, where a court suspended a related health funding agreement following concerns were raised about the safety of citizens' medical information.
After returning to office last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had administered aid for the American government, but Trump argued its spending was "inefficient" and his administration was seeking government-to-government deals to enhance transparency and accountability.
According to reports, 16 nations in Africa have to date signed similar agreements, constituting more than $18.3bn in new funding.
Details of the Rejected Agreement
The money for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this partnership would have delivered immense benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on HIV treatment through US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, with no equivalent guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that could be developed from that shared data," his statement read.
"In essence, our country would supply the basic resources for medical research with no certainty that the resulting innovations would be available to our population should a new pandemic emerge."
National Interest and International Frameworks
Mangwana further noted that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were disrupting structures already set up through the international organization.
The spokesperson cited its Pathogen Access and Benefit Sharing framework designed to manage potential global health emergencies.
"This system is designed to guarantee that when a nation contributes its data, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the resources to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage ongoing discussions with our US partners on how future co-operation might be arranged in a manner that respects the independence and dignity of each country."
Medical Community Reaction
Medical experts said it acknowledged the official position, but recommended that negotiations must proceed considering a large portion of the nation's HIV programmes relied on foreign aid.
"Where specific concerns arise, such as those involving data governance or agreement terms, these can often be addressed through technical clarification and negotiated safeguards," the group added.
This impasse emphasises the complex challenges between receiving much-needed international aid and safeguarding local interests in an increasingly interconnected world.